John D. Quisel Sells 12,791 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel sold 12,791 shares of Disc Medicine stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $66.01, for a total value of $844,333.91. Following the completion of the transaction, the chief executive officer now owns 72,065 shares of the company’s stock, valued at $4,757,010.65. The trade was a 15.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Disc Medicine Stock Performance

NASDAQ IRON traded down $1.50 during trading hours on Wednesday, hitting $63.50. The company had a trading volume of 327,848 shares, compared to its average volume of 347,116. The business has a 50 day moving average of $58.19 and a 200-day moving average of $50.24. The company has a market cap of $1.89 billion, a PE ratio of -15.95 and a beta of 0.76. Disc Medicine, Inc. has a 1-year low of $25.60 and a 1-year high of $77.60.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.15. Sell-side analysts expect that Disc Medicine, Inc. will post -4.05 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Disc Medicine in a report on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 target price on the stock. Morgan Stanley upgraded shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective on the stock in a report on Tuesday, November 5th. Wedbush reiterated an “outperform” rating and set a $83.00 target price on shares of Disc Medicine in a research note on Monday, December 9th. HC Wainwright reissued a “buy” rating and issued a $118.00 target price on shares of Disc Medicine in a report on Monday, December 9th. Finally, Raymond James raised Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their price target for the stock from $66.00 to $110.00 in a report on Monday, November 4th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $87.50.

Institutional Investors Weigh In On Disc Medicine

Large investors have recently modified their holdings of the company. Exome Asset Management LLC increased its holdings in shares of Disc Medicine by 5.8% in the 3rd quarter. Exome Asset Management LLC now owns 64,516 shares of the company’s stock valued at $3,170,000 after acquiring an additional 3,516 shares during the period. Teachers Retirement System of The State of Kentucky grew its position in Disc Medicine by 38.7% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 19,560 shares of the company’s stock worth $961,000 after purchasing an additional 5,458 shares during the last quarter. Geode Capital Management LLC grew its position in Disc Medicine by 17.6% during the 3rd quarter. Geode Capital Management LLC now owns 474,719 shares of the company’s stock worth $23,333,000 after purchasing an additional 70,983 shares during the last quarter. Barclays PLC boosted its stake in shares of Disc Medicine by 123.7% during the third quarter. Barclays PLC now owns 40,145 shares of the company’s stock worth $1,972,000 after buying an additional 22,202 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Disc Medicine during the third quarter worth about $445,000. 83.70% of the stock is owned by institutional investors and hedge funds.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.